Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric daprodustat trial for anemia associated with chronic kidney disease
NL-OMON53430Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of daprodustat in anemia of renal disease (2 arms), sponsored by GSK. Primary endpoint: Incidence of adverse events. Planned start Sep 2022; status: withdrawn.
02
Drugs
daprodustat
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on NL-OMON53430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53430.